Belfast, United Kingdom

Jaquin Thomas

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Fusion Antibodies Limited. Active years: 2016.



Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations by Jaquin Thomas in Cancer Therapy

Introduction

Jaquin Thomas is an accomplished inventor based in Belfast, GB. He has made significant contributions to the field of cancer therapy, particularly through his innovative approaches to targeting specific proteins involved in tumor growth.

Latest Patents

Jaquin Thomas holds a patent for a groundbreaking invention titled "Therapy targeting cathepsin S." This invention relates to a method of inhibiting chemotherapy-induced upregulation of Cathepsin S on the surface of tumor cells. The method involves the administration of a Cathepsin S inhibitor to these cells. Additionally, the patent provides a therapy that includes an anti-Cathepsin S antibody, which does not inhibit the proteolytic effect of Cathepsin S but effectively inhibits angiogenesis. Furthermore, it outlines a combination treatment that incorporates both a Cathepsin S inhibitor and a therapeutic agent. He has 1 patent to his name.

Career Highlights

Jaquin Thomas is currently associated with Fusion Antibodies Limited, where he continues to work on innovative solutions in the field of biotechnology. His expertise in cancer therapy has positioned him as a valuable asset in the research and development of new treatments.

Collaborations

Jaquin collaborates with talented individuals such as Shane Olwill and Christopher Scott, who contribute to the advancement of their shared goals in cancer research.

Conclusion

Jaquin Thomas's work in developing therapies targeting Cathepsin S represents a significant advancement in cancer treatment. His innovative approach and dedication to research continue to inspire progress in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…